Loading page…

Report overview

The report highlights LEO Pharma's 2019 revenue growth to DKK 10,805 million and completion of the Bayer prescription dermatology business integration. It also reports positive pivotal phase 3 results for tralokinumab, supporting preparation for regulatory filings. For sustainability, the company completed a materiality assessment to identify priorities for its strategy towards 2030.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Publication date: 25 February 2020
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services